Presence and metabolism of the anabolic steroid boldenone in various animal species: a review.

The review summarizes current knowledge on the possible illegal use of the anabolic steroid boldenone. The presence of' boldenone and metabolites in different animal species and the possibility of the occurrence of endogenous boldenone and metabolites is assessed, as are the methods of analysis used for detection. Different laboratories in the European Union have examined the occurrence of boldenone and its metabolites. The results were discussed at different meetings of a European Commission DG-SANCO Working Party) and summarized in an expert report. The situation of the different laboratories at this time is also covered herein. The overall conclusion of the Working Party was that there was a necessity for further research to distinguish between naturally occurring and illegally used boldenone forms. The confirmation of the presence of boldenone metabolites (free and conjugated forms) in certain matrices of animals is proposed as a marker for the illegal treatment with boldenone.

Application of 1D 1H NMR for fast non-targeted screening and compositional analysis of steroid cocktails and veterinary drug formulations administered to livestock.

A fast non-targeted strategy is described for analysis of formulations--meant for administration to live stock--containing growth-promoting agents or veterinary drugs. The use of 1H NMR as a first step universal screening method is applied and used in routine analysis. The implementation of this approach has increased the analysis efficiency considerably. Apart from screening on illegal compounds, 1H NMR information on matrix and thus, indirectly, administration mode, can be present. An ever-growing 1H NMR database is used containing more than 200 reference substances. Based on the 1H NMR screening, decisions for further analysis can be made, such as for instance HPLC fractionation of steroid cocktails and subsequent 1H NMR (and LC-MS) analysis. Examples of unravelling formulations are given in detail including a steroid cocktail containing 15 compounds.

Immunoaffinity chromatography for the sample pretreatment of Taxus plant and cell extracts prior to analysis of taxanes by high-performance liquid chromatography.

The application of immunoaffinity chromatography for the purification of Taxus plant and cell extracts prior to the HPLC analysis is described. Polyclonal antibodies raised against 10-deacetylbaccatin III (10-DAB III), paclitaxel's main precursor in plant, were characterised by enzymed-linked immunosorbent assay. Immunoglobulins from selected antisera were immobilised on CNBr-activated Sepharose 4B. The immunoaffinity column was used for the purification of plant and plant cell culture extracts prior to their analysis by HPLC. Immunoaffinity chromatography enabled the selective concentration of taxoids and enhanced sample clean-up.

Combinations of growth promoters in veal calves: consequences for screening and confirmation methods.

This study investigates the influence of low dosages of beta-agonists combined with other growth promoters on screening and confirmation methods in male veal calves. Five groups of four calves were treated for 6 weeks with combinations of low dosages of beta-agonists (beta AG, clenbuterol, mabuterol and mapenterol, 0.4 microgram/kg each twice daily) in combination with 17 beta-estradiol (E2, 5 mg per animal per 14 days), methylthiouracil (MTU, 2.857 mg/kg bw twice daily) and dexamethasone (DEX, 4 mg per animal per 10 days during the last 20 days of treatment). Another group of four untreated animals served as controls. The weight and size of the thymus was reduced in the DEX group, the MTU group showed enlarged thyroids. Histologically the prostates showed vacuolar degeneration in the beta AG animals and metaplasia in the E2 group. Some vacuolization was also observed in the controls. The testis showed impaired development in all treatment groups, E2 leading to the most severe changes. DEX led to cortical atrophy of the thymus. MTU induced hyperplastic changes in the thyroid. These results indicate that comedication does not markedly affect the histological changes induced in the hormonal target tissues. For screening purposes histology of the prostate can be used as a marker for oestrogens, whereas the weight of the thymus and thyroid can be used as an indication for the use of corticosteroids and thyreostatics, respectively. Vacuolization in the prostate appeared no reliable indication for beta-agonists. Samples of urine, faeces, liver and eye (retina/choroid) were analysed for beta-agonists. E2 significantly increased the levels of all beta-agonists in the liver and faeces, whereas DEX significantly reduced these levels. These observations show that additional medication with different groups of growth promoters can markedly alter the excretion of beta-agonists and thus influence (regulatory) control.

Illegal use of beta-adrenergic agonists: European Community.

The use of veterinary medicinal products within the European Community is governed by a series of directives and regulations that describe the requirements for safety, quality, and efficacy of these products. Veterinary therapeutic use of beta-agonists has only been approved in the case of clenbuterol for bronchodilatation in horses and calves and for tocolysis in cows. No beta-agonists have been permitted in the European Community for growth-promoting purposes in farm animals. Surveillance for the presence of residues of veterinary agents in food-producing animals and meat is regulated by the Directive 86/469/EEC containing specific guidelines for sampling procedures on farms and in slaughterhouses. The level and frequency of sampling is dependent on the category of compounds and animal species. When positive samples have been identified (above certain action levels), sampling intensity is increased. Results of monitoring programs in EU member states during 1992 and 1993 for the occurrence of residues of beta-agonists in food-producing animals vary substantially with respect to the percentages of positive samples, ranging from 0 to 7%. The variability is partly explained by differences in sampling strategies, detection methods, and action levels applied. Identification of the proper matrices for sampling and detection of beta-agonists is important. In the case of clenbuterol, hair and choroid retinal tissue are appropriate tissues because clenbuterol accumulates in these matrices. A clear decrease in the use of clenbuterol in cattle has been observed in The Netherlands, Germany, Northern Ireland, and Spanish Basque Country over the last 3 yr. This is partly due to intensified surveillance activities at farms and slaughterhouses by governmental agencies and production sector organizations. There are data on human intoxication following consumption of liver or meat from cattle treated with beta-agonists. At the concentrations of clenbuterol measured in contaminated liver and meat samples, pharmacological effects may be expected in humans after consuming 100 to 200 g of product. The use of highly active beta-agonists as growth promoters is not appropriate because of the potential hazard for human and animal health, as was recently concluded at the scientific Conference on Growth Promotion in Meat Production (Nov. 1995, Brussels).

Determination of embutramide and pentobarbital in meat and bone meal by gas chromatography-mass spectrometry.

An analytical procedure, consisting of multiple steps, was developed for the analysis of meat and bone meal for two veterinary drugs, embutramide and pentobarbital, used for euthanasia. After a combined extraction, embutramide was converted to its trimethylsilylether derivative and pentobarbital was methylated. Both analytes were determined by gas chromatography-mass spectrometry in the electron impact or chemical ionisation mode. Limits of determination and identification were between 50 and 100 micrograms kg-1 depending on the compound and the ionisation technique applied. Particular attention was focused on the identification of the analytes.

Multi-laboratory study of the analysis and kinetics of stanozolol and its metabolites in treated calves.

The European Union banned the use of anabolic steroids for cattle fattening in 1988. Analytical techniques able to detect trace amounts of the parent drugs and their metabolites are mandatory for the control of abuse. Stanozolol (Stan) is an anabolic steroid that is often found in injection sites and cocktails. However, it has never been detected in tissues (kidney fat, meat) or excreta (urine, faeces) taken during regulatory inspection. The difference between the structure of Stan and the other steroids (a pyrazole ring fused to the androstane ring system) is probably the cause of this phenomenon. In the multi-laboratory study described here, veal calves were treated with intramuscular doses of Stan. In the excreta of these calves the presence, absence and/or concentration of Stan and of its major metabolites 16 beta-hydroxystanozolol and 3'-hydroxystanozolol were determined. For the determination of these analytes the different laboratories used different extraction and clean-up procedures and also evaluated different analytical techniques such as GC-MS (negative chemical ionization) and LC-MS-MS. The aim of this investigation was to explore which analyte should be validated for veterinary inspection purposes.

Identification of metabolites of the anabolic steroid methandienone formed by bovine hepatocytes in vitro.

Monolayer cultures of bovine hepatocytes were used to investigate the biotransformation of methandienone in vitro. After incubation of bovine hepatocytes with methandienone, samples were taken at different times. The samples were treated with deconjugation enzymes and extracted with diethyl ether. The metabolites formed were converted to their trimethylsilylether derivatives. By using gas chromatography-mass spectrometry with electron impact and chemical ionisation, several metabolites were identified. After 24 h of incubation with bovine hepatocytes, 83% of the parent compound was converted to its metabolites. The major metabolite found was 6-beta-hydroxymethandienone with a yield of 24%. This compound was identified after comparison with an authentic sample of 6 beta-hydroxymethandienone, which was synthesized chemically.

Pour on application of growth promoters in veal calves: analytical and histological results.

To investigate the possibilities for screening and confirmation methods when the 'pour on' method of application is used for administration of growth promoters, an animal experiment was performed using a cocktail of a combination of growth promoters derived from (illegal) practice. Two cocktails were used, cocktail A consisting of stanozolol and estradiol benzoate and cocktail B consisting of stanozolol, estradiol benzoate and beclomethasone dipropionate. The intended dose per animal was 110 mg stanozolol, 25 mg estradiol and 10 mg beclomethasone. The experiment was performed on 20 male veal calves, 16 treated and 4 vehicle treated controls and 3 female veal calves, 2 treated and 1 vehicle treated control. Half of the animals were shaven prior to the application of the drugs. The cocktails were administered using two types of vehicles: vehicle A; Miglyol 840 with butylated hydroxytoluene and vehicle B; di(ethyleneglycol) monobutylether. During a 28 day treatment period, one group of animals was treated once a week, another group of animals was treated once every two weeks and slaughtered. Preliminary results showed that pour on application of anabolic steroids markedly increased growth performance of veal calves, the animals treated with cocktail A performed better than the animals treated with cocktail B. Macroscopically, the thymus was reduced in weight and size in the B animals. The bulbo-urethral glands were enlarged in all treated animals. Histologically all treated animals showed squamous metaplasia in the prostate, bulbo-urethral gland and Bartholins glands. Moreover, a changed secretion pattern was observed in both the prostate and the bulbo-urethral gland. Severe cortical atrophy was observed in the thymus and to a lesser extent the adrenals of the beclomethasone treated animals. The recently discovered 16 beta-hydroxy-metabolite of stanozolol was detected in urine, in relatively high concentrations. This is the first report of the excretion of this metabolite in urine after pour on administration showing the prospect for detection of dermal treatment. Estradiol levels were remarkably elevated (up to 200 micrograms l-1) exceeding the endogenous levels (< 1 microgram l-1).

A fast immunoassay for the screening of beta-agonists in hair.

Hair has been shown to be an excellent site for the accumulation of clenbuterol residues. Compared with other matrices, hair sampling is very easy and this might result in large numbers of samples. In this study, a simple digestion-extraction procedure was combined with a sensitive clenbuterol ELISA, which resulted in an easy screening procedure suitable for the detection of at least four beta-agonists. Hair from untreated cows (n = 40) resulted in low blank levels (0.9 +/- 0.7 and 0.5 +/- 0.2 ng g-1 for black and white hair, respectively). The detection limits for clenbuterol, bromobuterol, mapenterol and mabuterol were determined as 1-1.5 ng g-1 for white and 3-4 ng g-1 for black hair. The accumulation of mabuterol and mapenterol in black and white hair from treated calves was demonstrated by GC-MS. The screening assay is not suitable for the detection of cimbuterol (owing to the low extraction efficiency) and for salbutamol and terbutaline (owing to the low cross-reactivity of the antibodies used for the ELISA and the low extraction efficiency). Black hair samples from cows treated with clenbuterol were still found to be positive (> 5 ng g-1) at 23 weeks after treatment. The fast screening procedure is a powerful means to detect and track the illegal use of clenbuterol, bromobuterol, mabuterol and mapenterol in animal production.

beta-agonists in animal feed. III: Optimization of the clean-up and the end-determination step.

This study represents the second part of an interlaboratory study intended to develop an official modular Community confirmatory method for the detection of beta-agonists in animal feed. Homogeneous pools of primary extracts were prepared by means of an extraction module based on the conclusions of a previous part of this work. The primary extracts were further processed by four laboratories each using a different clean-up scheme. The final extracts thus obtained were cross-distributed between the same laboratories and measured either by GCMS or HPLC. Two laboratories (B and D) applied separate clean-up schemes for clenbuterol and salbutamol. All clean-up schemes for clenbuterol were found to be compatible with all end-determination steps. In contrast, for salbutamol clean-up method D was found not to be compatible with the end-determination steps applied by laboratories B and C. The results of this study have clearly demonstrated that the clean-up methods for both clenbuterol and salbutamol applied by laboratory B yielded superior recoveries with an acceptable standard deviation. Therefore, in conclusion to this study, the participating laboratories recommend the clean-up schemes applied by laboratory B to serve as part of the official Community confirmatory method.

Beta-agonists in animal feed. I: First intercomparison of methods of analysis for clenbuterol in animal feed materials.

The European Commission, Measurement and Testing Programme (BCR) has initiated a project to improve the methodology for analysis of beta-agonists in animal feeding stuffs. An intercomparison of methods for clenbuterol in animal feed is described. The study involved 13 European laboratories which analysed a blank feed and three feed samples with three different levels of clenbuterol contamination. The participants used a variety of extraction (organic or aqueous solvents), clean-up (liquid-liquid, silica and C-18 solid phase and immuno-affinity chromatography) and end-point detection (HPLC, GC-MS and TLC) steps. The purpose of this study was to identify and to quantify clenbuterol. The coefficient of variation from all the results for the low level (25 micrograms/kg) was 39%, for the intermediate level (100 micrograms/kg) 52% and for the high level (1000 micrograms/kg) 35%. The study showed that the initial extraction, the modular clean-up step and their compatibility to the HPLC and the GC-MS determination step were critical steps.

Beta-agonists in animal feed. II: Optimization of the extraction.

New projects of the European Commission, Measurement and Testing Programme (BCR) were set up in order to develop a modular sample preparation system for the determination of beta-agonists and animal feeds. Three phases are included: an extraction study, a clean-up study and finally a Second Intercomparison. This paper describes the extraction study in which four laboratories were involved. A total of 33 extraction conditions were tested regarding their yield on clenbuterol and salbutamol, their compatibility towards several clean-up and chromatographic end-methods and the influence of undesired coextractives. The conditions differed with respect to five factors: with or without organic solvent, temperature, pH, agitation and centrifugation. Their influence was examined via a ruggedness-test approach. A unique set-up allowed the combination of individual results in a complete factorial design. The addition of an organic solvent was found to be the most important factor. Interactions between factors were also studied. The best combinations of factors regarding the extraction are given. Finally limits for applicability and influence of organic solvents, pH and temperature were evaluated in a fifth laboratory towards enzyme immunoassay as detection method.

Determination of anabolic esters in oily formulations and plasma in husbandry using high-performance liquid chromatography and gas chromatography-mass selective detection.

Two different analytical methods are described for the analysis of anabolic steroid esters in oily formulations for veterinary use and animal plasma samples, respectively. For the determination of anabolic steroid esters in oily formulations (at mg kg-1 levels) a reversed-phase high-performance liquid chromatographic method with gradient elution is described. Gradient elution is performed owing to the relatively large variations in polarity of the investigated anabolic steroid esters. For the analysis of anabolic steroid esters in plasma (at ng ml-1 levels) two different strategies are applied. After solid-phase extraction, the plasma samples are introduced into the high-performance liquid chromatography (HPLC) system where the obtained fractions are then analysed by using gas chromatography-mass selective detection (GC-MSD). An alternative method is direct analysis of plasma samples after solid-phase extraction by using GC-MSD without any further clean-up procedure. Prior to GC-MSD the samples are derivatized to corresponding trifluoroacyl (TFA) derivatives. The calibration graph for HPLC is rectilinear over the range 25-150 ng ml-1 plasma and the analytical recoveries for medroxyprogesterone acetate (MPA) and testosterone propionate (TP) are more than 95%. The detection limits for both analytes in GC-MS are 2.5 ng ml-1 plasma for MPA and 0.5 ng ml-1 plasma for TP with an acceptable signal-to-noise ratio (calculated for the derivatized relative molecular mass). In the analysis of plasma obtained from animal experiments concentrations of 6.5 ng ml-1 are found for MPA by using GC-MSD and 5.0 ng ml-1 are found for nortestosterone laurate (NL) by using HPLC.

Screening of cattle urine samples for the presence of beta-agonists with a functional test: some preliminary results.

A new procedure based on the measurement of biological effects has been developed for the determination of residues of beta-agonists, such as clenbuterol, in urine. A multi-chamber superfusion apparatus containing isolated trachea strips from guinea pigs was used to detect smooth muscle relaxation induced via beta 2-adrenoceptor activation. The trachea tissue was pre-contracted with metacholine. Urine samples were extracted using a solid-phase column containing reversed-phase and anion-exchange materials. Extracts were introduced into the superfusion apparatus via flow injection. The intensity and response of relaxation are dependent on the type and concentration of the beta-agonist introduced. The sensitivity of the assay for clenbuterol in calf urine is about 1 microgram l-1. This methodology in the present form is especially suitable for survey screening analysis for several types of samples. An extensive validation of the procedure is performed to determine the range of analytes that can be detected, the possibilities of analysing urine samples obtained from mature cattle or other animal species and the influence of cross-reacting substances.

Determination of fenoterol and ractopamine in urine by enzyme immunoassay.

Fenoterol and ractopamine are phenethanolamines with beta-adrenergic agonist activity. An enzyme immunoassay (EIA) for these compounds was developed using antibodies raised in a New Zealand white rabbit against fenoterol-bovine serum albumin and fenoterol coupled to horseradish peroxidase (HRP). The calibration graphs of fenoterol and ractopamine showed linearity over the concentration ranges 0.1-5 and 0.2-25 ng ml-1, respectively. Isoxsuprine showed a cross-reactivity of 0.7% while the cross-reactivity of other beta-agonists was < 0.1%. The screening assay was used to detect fenoterol in urine samples obtained from an animal experiment in which male calves were treated with fenoterol (100 micrograms of fenoterol per kg of bodymass per meal for a period of four weeks). Using a direct method, without sample preparation, fenoterol concentrations ranged from 22 to 210 ng ml-1. The mean concentration of fenoterol after extraction in isobutanol was 3.5 times lower compared with the direct method. On applying enzymic hydrolysis in combination with isobutanol extraction, the mean concentration was eight times higher than that obtained when using extraction only. Gas chromatography-mass spectrometry (GC-MS) analysis confirmed the presence of fenoterol in most of these samples. However, probably owing to the absence of a proper GC-MS internal standard, the correlation between GC-MS and EIA concentrations was low (r = 0.7976). In general, the concentrations found by the EIA are much higher than those found by GC-MS, which might be caused by the presence of metabolites detected with the EIA. Fenoterol is excreted in urine mostly (about 85%) as glucuronidated-sulfated conjugate. The antibodies partly recognize the conjugated fenoterol, which makes it possible to use a direct screening assay. In blank calf urine the detection limits, mean background +3 times the standard deviation, are 1.3 (fenoterol) and 2.6 ng ml-1 (ractopamine). In bovine urine, however, owing to matrix effects, the detection limits are 20 times higher.

Primary leiomyosarcoma of bone: report of eight cases.

Eight primary leiomyosarcomas of bone were registered in the files of the Basel Bone Tumor Reference Center, Basel, Switzerland, for the period 1972 to 1990. The mean age of the patients (six males and two females) was 43.7 years (range, 11 to 87 years). The tumors were located in the long bones, the fingers, and the clavicle, and presented radiologically mainly as slightly to moderately aggressive lesions (grades IB to II according to Lodwick). They reacted immunohistochemically with antibodies against alpha-smooth muscle actin (alpha-SMA), and total muscle actins (eight of eight), vimentin (seven of eight), desmin (three of eight), keratin (four of eight), type IV collagen (six of eight), laminin (five of eight), and S-100 (one of eight). Seven patients underwent surgery (five, resection; two, amputation). Some of them had received preoperative or adjuvant chemotherapy or radiation therapy. One patient with a metastasized tumor had received chemotherapy only. Tumor recurrences were observed in two cases. Four patients developed metastases of whom two were treated with chemotherapy or tumor resection. During a follow-up period of 1 to 72 months (mean, 46.5 months) four of the eight patients survived for up to 72 months, among them the only patient with grade 3 tumor and treated metastases.

Determination of beta-sympathomimetics in liver and urine by immunoaffinity chromatography and gas chromatography-mass-selective detection.

A specific and sensitive method for the determination of several beta-agonistic drugs in liver and urine is described. Following clean-up by immunoaffinity chromatography and two different derivatizations, gas chromatography-mass spectrometry with electron-impact ionization is performed. The immunoaffinity chromatography columns were packed with Sepharose-immobilized polyclonal antibodies raised against the beta-agonist clenbuterol. Owing to the high clean-up efficiency of the immunoaffinity column large sample volumes can be used (up to 100 ml urine or 25 gram liver). The immunoaffinity sample pretreatment is highly specific and no further sample pretreatment was necessary. Due to the combination of two different derivatizations only GC-MS with electron-impact ionization is necessary to fulfil legal requirements. The first confirmation step consists of a derivatization reaction between the hydroxyl group of the parent compound and trimethylsilane. The second confirmation method is a derivatization to a cyclic derivative with the hydroxyl group and the aliphatic nitrogen group. Limits of determination in liver as well in urine are at the 10 ng/kg or ng/l (ppt) level with acceptable signal-to-noise ratio. The method is suitable for identification and quantification of trace amounts of several similar beta-agonistic drugs either used separately or in combination and can be used also for quantification of clenbuterol in liver with regard to levels exceeding the maximum residue limit (MRL) of 1 microgram/kg (ppb).

Test strip enzyme immunoassays and the fast screening of nortestosterone and clenbuterol residues in urine samples at the parts per billion level.

The preliminary results of an investigation into the development of "on-site" test strip enzyme immunoassays for the screening of urine samples for the presence of growth promoters, such as 17 beta, 19-nortestosterone and clenbuterol at the parts per billion level are described. Urine samples, enzyme-labelled analyte and a nitrocellulose test strip, containing immobilized antibodies, are incubated together, after which the strip is placed in a chromogen-containing substrate solution for colour reaction. Using prefabricated strips, the tests can be performed in 45-60 min. A similar assay was worked out using a dot-blotting device, allowing the test to be performed in 20-50 min. The tests are simple and easy to perform outside the laboratory. Urine samples identified positive by gas chromatography mass spectrometry were also found to be positive with these test strips and, so far, no false-positive results have been encountered. With standard additions to blank urine samples, positive samples could be distinguished above the 5 ng ml level. However, samples from treated calves contain one or more metabolites of the parent compound, which increase the sensitivity of the assays. Although the tests described can be improved and still have to be evaluated further by analysing more urine samples, the preliminary results are very promising and give a lead to further research into the applicability of such "on-site" tests in residue analysis.

Determination of clenbuterol in urine of calves by high-performance liquid chromatography with in series ultraviolet and electrochemical detection.

A method for the determination of clenbuterol in calf urine is described. After a simple two-step sample pretreatment, involving an Extrelut-3 column and a solid-phase extraction column (C2), the separation of clenbuterol from interfering compounds present in urine samples was performed with ion-pair chromatography on a LiChrospher RP-Select-B column with a mixture of acetonitrile and sodium dodecyl sulphate/acetate buffer (pH 3.5) as mobile phase. To obtain a higher specificity, two different physico-chemical detection techniques, i.e. UV-absorption (244 nm) and electrochemical detection (+1250 mV), were applied in series. The lowest limit of determination was 0.5 ng ml-1 and the mean recovery of clenbuterol spiked at 10 ng ml-1 level was 79.9% (RSD = 6.3%; n = 9). The analysis of one urine sample, including sample preparation, took less than 2 h. Results obtained with this method correlated well with GC-MS analysis. With the described method about 400 urine samples were analysed. In a pilot experiment, in which a calf received orally 4 micrograms clenbuterol.HCl per kilogram body weight twice a day (five times the therapeutic dose for oral application) for 5 days, the highest concentration of clenbuterol found in urine was 73 ng ml-1. In a second experiment, in which two calves received the therapeutic dose of clenbuterol.HCl twice a day over a period of 2 weeks, the highest concentration of clenbuterol was 75 ng ml-1 of urine. Eight days after the final application, concentrations of clenbuterol were lower than 0.5 ng ml-1. From this excretion study for clenbuterol a half-life value of approximately 1.5 days was calculated.